Literature DB >> 31395440

Pharmacogenomics.

Dan M Roden1, Howard L McLeod2, Mary V Relling3, Marc S Williams4, George A Mensah5, Josh F Peterson6, Sara L Van Driest7.   

Abstract

Genomic medicine, which uses DNA variation to individualise and improve human health, is the subject of this Series of papers. The idea that genetic variation can be used to individualise drug therapy-the topic addressed here-is often viewed as within reach for genomic medicine. We have reviewed general mechanisms underlying variability in drug action, the role of genetic variation in mediating beneficial and adverse effects through variable drug concentrations (pharmacokinetics) and drug actions (pharmacodynamics), available data from clinical trials, and ongoing efforts to implement pharmacogenetics in clinical practice.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31395440      PMCID: PMC6707519          DOI: 10.1016/S0140-6736(19)31276-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  107 in total

1.  Unusual responses to drugs in some hereditary conditions.

Authors:  W KALOW
Journal:  Can Anaesth Soc J       Date:  1961-01

2.  Drug reactions enzymes, and biochemical genetics.

Authors:  A G MOTULSKY
Journal:  J Am Med Assoc       Date:  1957-10-19

3.  Medical genetics: a marker for Stevens-Johnson syndrome.

Authors:  Wen-Hung Chung; Shuen-Iu Hung; Hong-Shang Hong; Mo-Song Hsih; Li-Cheng Yang; Hsin-Chun Ho; Jer-Yuarn Wu; Yuan-Tsong Chen
Journal:  Nature       Date:  2004-04-01       Impact factor: 49.962

4.  Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.

Authors:  S Mallal; D Nolan; C Witt; G Masel; A M Martin; C Moore; D Sayer; A Castley; C Mamotte; D Maxwell; I James; F T Christiansen
Journal:  Lancet       Date:  2002-03-02       Impact factor: 79.321

5.  Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.

Authors:  Mark J Rieder; Alexander P Reiner; Brian F Gage; Deborah A Nickerson; Charles S Eby; Howard L McLeod; David K Blough; Kenneth E Thummel; David L Veenstra; Allan E Rettie
Journal:  N Engl J Med       Date:  2005-06-02       Impact factor: 91.245

6.  Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.

Authors:  Marianne Abifadel; Mathilde Varret; Jean-Pierre Rabès; Delphine Allard; Khadija Ouguerram; Martine Devillers; Corinne Cruaud; Suzanne Benjannet; Louise Wickham; Danièle Erlich; Aurélie Derré; Ludovic Villéger; Michel Farnier; Isabel Beucler; Eric Bruckert; Jean Chambaz; Bernard Chanu; Jean-Michel Lecerf; Gerald Luc; Philippe Moulin; Jean Weissenbach; Annick Prat; Michel Krempf; Claudine Junien; Nabil G Seidah; Catherine Boileau
Journal:  Nat Genet       Date:  2003-06       Impact factor: 38.330

7.  Rapid, long-range molecular haplotyping of thiopurine S-methyltransferase (TPMT) *3A, *3B, and *3C.

Authors:  Nicolas von Ahsen; Victor W Armstrong; Michael Oellerich
Journal:  Clin Chem       Date:  2004-07-09       Impact factor: 8.327

8.  Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2.

Authors:  Simone Rost; Andreas Fregin; Vytautas Ivaskevicius; Ernst Conzelmann; Konstanze Hörtnagel; Hans-Joachim Pelz; Knut Lappegard; Erhard Seifried; Inge Scharrer; Edward G D Tuddenham; Clemens R Müller; Tim M Strom; Johannes Oldenburg
Journal:  Nature       Date:  2004-02-05       Impact factor: 49.962

9.  Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients.

Authors:  Munir Pirmohamed; Sally James; Shaun Meakin; Chris Green; Andrew K Scott; Thomas J Walley; Keith Farrar; B Kevin Park; Alasdair M Breckenridge
Journal:  BMJ       Date:  2004-07-03

10.  Warfarin therapy is feasible in CYP2C9*3 homozygous patients.

Authors:  Jacob Ablin; Shaltiel Cabili; Amiram Eldor; Ayala Lagziel; Hava Peretz
Journal:  Eur J Intern Med       Date:  2004-02       Impact factor: 4.487

View more
  83 in total

1.  Sources of Interindividual Variability.

Authors:  Yvonne S Lin; Kenneth E Thummel; Brice D Thompson; Rheem A Totah; Christi W Cho
Journal:  Methods Mol Biol       Date:  2021

Review 2.  Heart failure in single right ventricle congenital heart disease: physiological and molecular considerations.

Authors:  Anastacia M Garcia; Jonathan-Thomas Beatty; Stephanie J Nakano
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-02-28       Impact factor: 4.733

Review 3.  Use of Real-World Evidence in US Payer Coverage Decision-Making for Next-Generation Sequencing-Based Tests: Challenges, Opportunities, and Potential Solutions.

Authors:  Patricia A Deverka; Michael P Douglas; Kathryn A Phillips
Journal:  Value Health       Date:  2020-03-26       Impact factor: 5.725

Review 4.  Genetic polymorphisms associated with upper gastrointestinal bleeding: a systematic review.

Authors:  Marcela Forgerini; Rosa Camila Lucchetta; Gustavo Urbano; Tales Rubens de Nadai; Patrícia de Carvalho Mastroianni
Journal:  Pharmacogenomics J       Date:  2020-09-18       Impact factor: 3.550

5.  Pharmacogenetic/Pharmacogenomic Tests for Treatment Prediction in Depression.

Authors:  Farhana Islam; Ilona Gorbovskaya; Daniel J Müller
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

6.  The Pharmacogenetics of Rituximab: Potential Implications for Anti-CD20 Therapies in Multiple Sclerosis.

Authors:  Michael Zhong; Anneke van der Walt; Maria Pia Campagna; Jim Stankovich; Helmut Butzkueven; Vilija Jokubaitis
Journal:  Neurotherapeutics       Date:  2020-10-14       Impact factor: 7.620

Review 7.  Strategic vision for improving human health at The Forefront of Genomics.

Authors:  Eric D Green; Chris Gunter; Leslie G Biesecker; Valentina Di Francesco; Carla L Easter; Elise A Feingold; Adam L Felsenfeld; David J Kaufman; Elaine A Ostrander; William J Pavan; Adam M Phillippy; Anastasia L Wise; Jyoti Gupta Dayal; Britny J Kish; Allison Mandich; Christopher R Wellington; Kris A Wetterstrand; Sarah A Bates; Darryl Leja; Susan Vasquez; William A Gahl; Bettie J Graham; Daniel L Kastner; Paul Liu; Laura Lyman Rodriguez; Benjamin D Solomon; Vence L Bonham; Lawrence C Brody; Carolyn M Hutter; Teri A Manolio
Journal:  Nature       Date:  2020-10-28       Impact factor: 49.962

Review 8.  Pharmacogenomic Approach to Antimyopia Drug Development: Pathways Lead the Way.

Authors:  Tatiana V Tkatchenko; Andrei V Tkatchenko
Journal:  Trends Pharmacol Sci       Date:  2019-10-30       Impact factor: 14.819

Review 9.  Pediatric pharmacogenomics: challenges and opportunities: on behalf of the Sanford Children's Genomic Medicine Consortium.

Authors:  David Gregornik; Daria Salyakina; Marilyn Brown; Samuel Roiko; Kenneth Ramos
Journal:  Pharmacogenomics J       Date:  2020-08-26       Impact factor: 3.550

Review 10.  Precision medicine for rheumatologists: lessons from the pharmacogenomics of azathioprine.

Authors:  Laura L Daniel; Alyson L Dickson; Cecilia P Chung
Journal:  Clin Rheumatol       Date:  2020-07-02       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.